Could a simple drug shorten labor? new trial tests papaverine
NCT ID NCT07237880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single dose of papaverine, a muscle relaxant, can safely shorten the second stage of labor in pregnant women who had a balloon catheter to start labor. Researchers will compare labor times and outcomes between women who get papaverine and those who get a placebo. The trial aims to find a simple way to reduce labor duration and improve the birth experience.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- papaverine
- What this could lead to
- If it works, this could offer a simple, safe way to shorten labor for women after cervical ripening, potentially reducing discomfort and complications.
- What could go wrong
- This is an early-stage trial with only 184 participants. The drug may not shorten labor significantly, and there is a small risk of side effects like allergic reactions or effects on the baby.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 184 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pregnant individuals aged 18-50 years * Singleton pregnancy * Gestational age 37-42 weeks * Admission for induction of labor with a double-balloon catheter * Planned vaginal delivery * Ability to provide informed consent Exclusion Criteria: * Previous cesarean delivery * Multiple gestation * Contraindication to vaginal delivery * Known hypersensitivity to papaverine * Known major fetal anomaly * Any condition requiring immediate delivery or precluding safe participation (as determined by the treating physician)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Labor, induced are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hillel Yaffe Medical Center
RECRUITINGHadera, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Simple finger sweep vs balloon: which gets labor started better?
- Which Labor-Inducing drug works best for First-Time moms?
- Which labor induction method is safer for moms and babies?
- Does knowing more about labor induction make childbirth better?
- Can a numbing cream make labor induction less painful?
- Could a simple pill let women start labor at home?